Three clinical trials of Neuragen have been completed to date with 160 patients.
The graphs below depict results from a double blind placebo controlled trial by independent researchers at Louisiana State University. 60 subjects experiencing all-cause neuropathic foot pain and a sub group suffering from diabetic neuropathy were treated with Neuragen. In both cases greater than 90% of participants received significant pain relief.
60 subjects with all-cause neuropathic foot pain were treated in a randomized, double blind placebo controlled trial. The graph below represents the average pain level for all participants before treatment (time=0) and for up to 9 hours after treatment with either Neuragen (blue drops) or placebo (grey triangles). Pain relief with Neuragen was statistically significant vs. baseline for up to 8 hours in duration.
Another commonly accepted way to analyze data from pain trials is to compare the number of patients who received at least a 50% reduction in pain level vs. placebo. As shown on the left, 52% of subjects receiving Neuragen benefited from a 50% or greater reduction in pain within 30 minutes, vs. only 3% in the placebo group.
Download a PDF of Clinical Research Reviews
View a pdf of the Neuragen study entitled: Research article The effect of Neuragen PN® on Neuropathic pain: A randomized, double blind, placebo controlled clinical trial